Changes in use of antiretroviral therapy in regions of Europe over time

AIDS

Volumn 12, Issue 15, 1998, Pages 2031-2039

  Kirk, Ole ^a,j   Mocroft, Amanda ^b   Katzenstein, Terese L ^c   Lazzarin, Adriano ^d   Antunes, Francisco ^e   Francioli, Patrick ^f   Brettle, Ray P ^g   Parkin, Jacqueline M ^h   Gonzales Lahoz, Juan ⁱ   Jens, D ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c Rigshospitalet   (Denmark)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g CITY HOSPITAL   (United Kingdom)

^h ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁱ Hospital del Rey   (Spain)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Combination therapy; Components of combination therapy; HIV infection; Protease inhibitor; Regional differences in Europe

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG USE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 7844246144     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00015     Document Type: Article

References (23)

1. Collier AC, Coombs RW, Fischl MA, et al.: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993, 119:786-793.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500/μl. N Engl J Med 1996, 335:1081-1090.
3. Delta Coordinating Committee: Delta: a randomised controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
4. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
5. CAESAR Coordinating Committee: Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR Trial. Lancet 1997, 349:1413-1421.
6. Hoggs RS, O'Shaughnessy MV, Galaric N, et al.: Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997, 349:1294.
7. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 336:725-773.
8. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
10. BHIVA Guidelines Co-ordinating Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
11. Lundgren JD, Phillips AN, Vella S, et al.: Factors associated with use of antiretrovirals and primary prophylaxis in 3122 European HIV-infected patients. J Acquir Immune Defic Syndr 1997, 16:153-160.
12. Moore RD, Keruly JC, Chaisson RE: Duration of the survival benefit of zidovudine therapy in HIV infection. Arch Intern Med 1996, 156:1073-1077.
13. Melnick SL, Sherer R, Louis TA, et al.: Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994, 272:1915-1921.
14. Hoggs RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
15. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
16. Lundgren JD, Pedersen C, Clumeck N, et al.: Survival differences in European AIDS patients 1979-1989. BMJ 1994, 308:1068-1073.
17. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:185-191.
18. Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990, 322:941-949.
19. Fischl MA, Richman DD, Hansen N, et al.: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990, 112:727-737.
20. Lundgren JD, Phillips AN, Pedersen C, et al.: Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994, 271:1088-1092.
21. Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L: Saquinavir vs zalcitabine vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take zidovudine. XI international Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.410].
22. Cameron DV, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998, 351:543-549.
23. Cohen C, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination therapy in HIV-infected patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract LB7b].